
Innate Pharma S.A. IPHA
€ 1.12
-5.11%
Geschäftsbericht 2024
hinzugefügt 21.03.2026
Innate Pharma S.A. EV 2011-2026 | IPHA
EV Jährlich Innate Pharma S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 259 M | 288 M | 412 M | 132 M | 69.7 M | 195 M | 234 M | 16.1 M | 15.6 M | 24.9 M | 33.5 M |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 412 M | 15.6 M | 153 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Lipocine
LPCN
|
17 M | $ 7.4 | 1.23 % | $ 39 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
849 M | $ 217.23 | -0.38 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 19.47 | 1.25 % | $ 910 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
119 M | $ 8.28 | -1.84 % | $ 110 M | ||
|
Lexicon Pharmaceuticals
LXRX
|
635 M | $ 1.68 | 2.13 % | $ 610 M | ||
|
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
169 M | $ 0.74 | 21.89 % | $ 8.48 M | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
11.9 B | $ 41.51 | 0.23 % | $ 11.3 B | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.36 | -3.21 % | $ 347 M | ||
|
MediWound Ltd.
MDWD
|
32 M | $ 16.64 | -1.42 % | $ 453 M | ||
|
Mesoblast Limited
MESO
|
1.4 B | $ 14.31 | 2.07 % | $ 9.29 B | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | ||
|
Genmab A/S
GMAB
|
27 B | $ 25.73 | 0.19 % | $ 16.5 B | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.61 | -0.76 % | $ 16.4 M | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Immatics N.V.
IMTX
|
503 M | $ 9.19 | -3.36 % | $ 578 M | ||
|
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.34 | -1.92 % | $ 832 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
15.6 B | $ 69.55 | -1.75 % | $ 11.1 B | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | ||
|
Longeveron
LGVN
|
16.9 B | $ 0.87 | -8.8 % | $ 15.3 B | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M |